1 Internal Medicine Department, Mountain View Hospital Sunrise Health Consortium, Las Vegas, NV.
2 Associate Program Director, Mountain View Hospital Associate Professor of Medicine, University of Nevada.
3 Division Director of Research HCA Far West Division, Las Vegas, NV.
4 Associate Program Director, Mountain View Hospital Professor of Medicine, TCU and UNTHSC School of Medicine, Fort Worth, TX.
5 Gastroenterology Fellowship Department, Southern Hills Hospital and Medical Center, Las Vegas, NV.
World Journal of Advanced Research and Reviews, 2021, 10(01), 230-236
Article DOI: 10.30574/wjarr.2021.10.1.0165
DOI url: https://doi.org/10.30574/wjarr.2021.10.1.0165
Received on 14 March 2021; revised on 19 April 2021; accepted on 21 April 2021
Only a few studies are available with appropriate data on the effects of non-aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) use in patients with fatty liver disease. We performed a retrospective study of 1347 patients with imaging studies that showed fatty liver disease from 2016 through 2019. We then determined the change in validated indices using Fibrosis-4 (FIB4) and NAFLD fibrosis score (NFS). Patient clinical information, including NSAIDs use, was collected at baseline and then yearly. Using generalized linear models, we estimated the association between non-aspirin NSAIDs use and change in baseline indices. Non-aspirin NSAIDs use was found to be associated with significant lowering of FIB-4 score (0.596 units lower, p-value <0.0001) and NFS (0.431 units lower, p-value 0.0027) every year.
In this retrospective study of patients with fatty liver disease found on imaging, non-aspirin NSAID use was associated with lowering of fibrosis scores, suggesting that NSAID use might be associated with a lower risk for advanced fibrosis in fatty liver disease.
Fatty liver disease; NSAIDs; Aspirin; Ibuprofen; liver fibrosis; Advance liver disease, Cirrhosis, liver fibrosis indices, NAFLD score, Fibrosis-4 score
Preview Article PDF
Ikechukwu Ronald Ogbu, Hossein Akhondi asl, Napatkamon Ayutyanont, Andre Manov and Vignan Manne. Non-aspirin NSAIDs use is associated with lowering of liver fibrosis scores in patients with fatty liver disease. World Journal of Advanced Research and Reviews, 2021, 10(01), 230-236. Article DOI: https://doi.org/10.30574/wjarr.2021.10.1.0165
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0